

FOI Request: atypical Haemolytic Uraemic Syndrome (“aHUS”) and Soliris (eculizumab)
Our Reference Number: 1314023

Please send us the following information in regard to the period 1 October 2011 to date:-

- **Information on any formulary or prescription or funding of treatment policies your CCG holds and applies in regard to the treatment of aHUS with Solaris or eculizumab and a copy of such relevant policy in the relevant period.**
- **Information on the number of applications made for IFR treatment of aHUS with Solaris or eculizumab in the relevant period which were granted without need for any appeal within the CCG IFR policy.**
- **Information on the number of appeals made after IFR refusals of applications for treatment for aHUS with Solaris or eculizumab**
- **Information on the number of appeals made after IFR refusals of applications for treatment for aHUS with Solaris or eculizumab which were successful in that they resulted in the funding of treatment for aHUS with Solaris or eculizumab**
- **Information on the number of patients within your CCG who are currently receiving treatment for aHUS with Solaris or eculizumab through the procedure of IFR applications and/or appeals.**
- **Information on the IFR policy conditions of your CCG which apply to an application and appeal for treatment of aHUS with Solaris or eculizumab**
- **Information on the number of Judicial Review claims against the CCG made by individual patients or groups of patients following refusal of applications and appeals under IFR for treatment of aHUS with Solaris or eculizumab in the relevant period.**

Essex Clinical Commissioning Group's (CCG) do not hold any guidelines for aHUS with Sorliris or Eculizumab therefore applications would be reviewed on a case per case basis.

Please note that Essex CCG's have not received any applications for treatment of aHUS with Solirus or Eculizumab between 1st October 2011 to date.

Please find attached the IFR policy and patient leaflet which is currently being updated



4 - IFR patient info
leaflet updated feb 1:



ifr-policy[1].pdf